难治性分化型甲状腺癌的治疗进展

佳琪 杨(承德医学院研究生院，中国;)
永昌 席(保定市第一中心医院核医学科，中国;)
贺松 李(承德医学院研究生院，中国;)
会民 宋(保定市第一中心医院核医学科，中国;)
秋霞 王(保定市第一中心医院核医学科，中国;)

摘要

近年来,作为最常见的恶性肿瘤之一,甲状腺癌的发病率曲线明显上升。分化型甲状腺癌（DTC）经过手术、131I 放疗及促甲状腺激素抑制等治疗后, 大多数患者总体预后良好。但仍有少部分患者对放射性碘治疗不敏感且有1个或多个癌基因的突变,则成为病情进展快、死亡率高的碘难治性分化型甲状腺癌（Refractory Differentiated Thyroid Cancer, RDTC），占分化型甲状腺癌患者的2%~5%，10年生存率不足10%。本文综述近10年RDTC的治疗策略更新，涵盖靶向药物、放射性核素治疗及免疫疗法。

关键词

碘难治性；难治性分化型甲状腺癌；核素治疗；靶向治疗；研究进展

参考

张芳蕾, 周振虎. 安罗替尼对碘难治性分化型甲状腺癌的短期疗效评价及安全性研究[J]. 临床医学进展, 2023, 13(10): 15415-15422.

黄韬,胡丽丽,周军.难治性分化型甲状腺癌的研究进展[J].东南大学学报(医学版), 2017, 36(005):876-881.

NOUIAKH L, KARIMA OUALLA, OUAHBI H, et al. Refractory Thyroid Carcinomas: Experience of the Medical Oncology Department of Hassan II Hospital in Fez, Morocco[J/OL]. International Journal of Innovative Research in Medical Science, 2020, 5(12): 606-610[2025-06-08].

刘欣,林琳,樊蓉,等.碘难治性分化型甲状腺癌的预后及影响因素分析[J].中国辐射卫生, 2024, 33(5):566-572.

IBRAHIMPASIC T, GHOSSEIN R, SHAH J P, et al. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects[J/OL]. Thyroid, 2019, 29(3): 311-321[2025-06-08].

LIU Y, WANG Y, ZHANG W. Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: a retrospective study[J/OL]. EJNMMI Research, 2022, 12(1): 45[2025-06-08].

SCHMIDT A, IGLESIAS L, KLAIN M, et al. Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation[J/OL]. Archives of Endocrinology and Metabolism, 2017, 61(1): 81-89[2025-06-08].

郭雪冉, 赵玮, 张梦夏, 等. 碘难治性分化型甲状腺癌危险因素及预后分析[J/OL]. 安徽医学, 2024, 45(9): 1137-1141.

陈文捷, 王亚兵, 陈晓琳, 等. 碘难治性分化型甲状腺癌的最新研究进展[J/OL]. 中国临床药理学与治疗学, 2022, 27(1): 116-120.

赵丹, 梁军, 林岩松. 碘难治性分化型甲状腺癌相关发生机制研究进展[J/OL]. 癌症进展, 2013, 11(1): 36-40.

O’NEILL C J, OUCHAREK J, LEAROYD D, et al. Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer[J/OL]. The Oncologist, 2010, 15(2): 146-156[2025-06-08].

ZHANG L, LI Z, ZHANG M, et al. Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer[J/OL]. Medical Oncology, 2023, 40(9): 258[2025-06-08].

SCHLUMBERGER M, TAHARA M, WIRTH L J, et al. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer[J/OL]. New England Journal of Medicine, 2015, 372(7): 621-630[2025-06-08].

FLEEMAN N, HOUTEN R, BAGUST A, et al. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation[J/OL]. Health Technology Assessment, 2020, 24(2): 1-180[2025-06-08].

PITOIA F, JERKOVICH F. Selective use of sorafenib in the treatment of thyroid cancer[J/OL]. Drug Design, Development and Therapy, 2016: 1119[2025-06-08].

HAROON AL RASHEED M R, XU B. Molecular Alterations in Thyroid Carcinoma[J/OL]. Surgical Pathology Clinics, 2019, 12(4): 921-930[2025-06-08].

王智颖, 耿良. 碘难治性甲状腺癌靶向药物的研究进展[J/OL]. 山东医药, 2019, 59(10): 103-106.

SU J Y. Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation[J/OL]. American Journal of Cancer Research, 2024, 14(2): 407-428[2025-06-08].

田迅, 戴晨阳, 苏瑞, 等. 酪氨酸激酶靶向药物在难治性甲状腺癌治疗中的应用研究进展[J/OL]. 山东医药, 2019, 59(6): 99-102.

Herceg D , Herceg G H .Targeted therapy in patients with radioiodine-refractory differentiated thyroid cancer (DTC)[J].Periodicum Biologorum, 2014, 116(4):str.399-407.

LI J, ZHANG X, MU Z, et al. Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review[J/OL]. Frontiers in Immunology, 2022, 13: 943916[2025-06-08].

赵柳燕, 宋守君, 薛海波. 分子靶向药物治疗难治性甲状腺癌的疗效及安全性的meta分析[J/OL]. 国际医药卫生导报, 2022, 28(17): 2369-2376[2025-06-08].

VOLPE F, NAPPI C, ZAMPELLA E, et al. Current Advances in Radioactive Iodine-Refractory Differentiated Thyroid Cancer[J/OL]. Current Oncology, 2024, 31(7): 3870-3884[2025-06-08].

CHEN J, XIAO Z, WU H. Research progress of immunotherapy against anaplastic thyroid cancer[J/OL]. Frontiers in Oncology, 2024, 14: 1365055[2025-06-08].

S. Leboulleux, C. Cao et al. “MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956).” Journal of the Endocrine Society[2021-05-03]

CHENG W, LIU R, ZHU G, et al. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells[J/OL]. The Journal of Clinical Endocrinology & Metabolism, 2016, 101(3): 962-971[2025-06-08].

WEBER M, KERSTING D, RIEMANN B, et al. Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study[J/OL]. Clinical Cancer Research, 2022, 28(19): 4194-4202[2025-06-08].

BOHR A, MEMARZADEH K. The rise of artificial intelligence in healthcare applications[M/OL]//Artificial Intelligence in Healthcare. Elsevier, 2020: 25-60[2025-06-08].

RIEDL J M, MOIK F, ESTERL T, et al. Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view[J/OL]. Virchows Archiv, 2024, 484(2): 169-179[2025-06-08].

MUKHERJEE S. Genomics-Guided Immunotherapy for Precision Medicine in Cancer[J/OL]. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34(8): 487-497[2025-06-08].

DUAN X P, QIN B D, JIAO X D, et al. New clinical trial design in precision medicine: discovery, development and direction[J/OL]. Signal Transduction and Targeted Therapy, 2024, 9(1): 57[2025-06-08].

SINGLA P, MUSYUNI P, AGGARWAL G, et al. Precision Medicine: An Emerging Paradigm for Improved Diagnosis and Safe Therapy in Pediatric Oncology[J/OL]. Cureus, 2021[2025-06-08].

LIN J Z, LONG J Y, WANG A Q, et al. Precision medicine: In need of guidance and surveillance[J/OL]. World Journal of Gastroenterology, 2017, 23(28): 5045[2025-06-08].

CRABTREE B, BOOTMAN J L, BOYLE C J, et al. Aligning the AACP Strategic Engagement Agenda with Key Federal Priorities in Health: Report of the 2016-17 Argus Commission[J/OL]. American Journal of Pharmaceutical Education, 2017, 81(8): S15[2025-06-08].

MATRONE A, CAMPOPIANO M C, NERVO A, et al. Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine[J/OL]. Frontiers in Endocrinology, 2020, 10: 884[2025-06-08].

MARTÍNEZ TRUFERO J, CAPDEVILLA J, CRUZ J J, et al. SEOM clinical guidelines for the treatment of thyroid cancer[J/OL]. Clinical and Translational Oncology, 2011, 13(8): 574-579[2025-06-08].

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v8i6.29048